USA flag logo/image

An Official Website of the United States Government

Radioprotection by use of Topical Lithium Formulations

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93495
Program Year/Program:
2009 / STTR
Agency Tracking Number:
CA130191
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CUMBERLAND PHARMACEUTICALS, INC.
CUMBERLAND PHARMACEUTICALS INC. 2525 WEST END AVE, STE 950 NASHVILLE, TN 37203
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Radioprotection by use of Topical Lithium Formulations
Agency: HHS
Contract: 1R41CA130191-01A2
Award Amount: $121,528.00
 

Abstract:

DESCRIPTION (provided by applicant): Roughly 500,000 cancer patients are treated with radiotherapy each year. Acute and late sequelae of radiotherapy have a negative impact upon the quality of life of cancer survivors. These sequelae include proctitis, cys titis, esophageal stricture, cutaneous fibrosis plus others. We propose a novel means of preventing the acute and late radiation injury to normal tissues in these patients. Inhibitors of GSK-32 pathway can serve as radiation protective agents. Lithium can inhibit the GSK-32 pathway. Lithium-containing topical formulations are candidates for being effective radioprotectors by delivering the metal ion to the basal cell layer of epidermis (progenitor cells), preventing radio-induced apoptosis in normal cells i n the skin overlying areas of radiation treatment. A total 12 prototype formulations will be screened in a radiation-induced injury porcine model. Six of the formulations will contain lithium succinate and the other six will contain lithium lactate. Two le vels of the lithium salts will be screened (1% and 10%), each as an ointment, a gel, and an emulsion (cream). The best formulation(s) will be selected based on induction of proteins that enhance cell viability and inhibition of radiation-induced apoptosis. The efficacy and safety of selected formulations will be optimized in Phase II, supporting proof-of-concept for testing in humans and an IND submission to the FDA. PUBLIC HEALTH RELEVANCE: Over 500,000 cancer patients are treated with radiotherapy each year, and there are presently 10,000,000 cancer survivors in the US. Acute and late sequelae of radiotherapy have a negative impact upon the quality of life of cancer survivors. The goal of this proposal is to attenuate skin injury through developmen t of a topical drug that markedly enhances the viability of the epidermis when administered before irradiation therapy to cancer patients undergoing targeted treatment of deeper tumors with radiation therapy.

Principal Investigator:

Dennis E. Hallahan
3143629700
DHALLAHAN@RADONC.WUSTL.EDU

Business Contact:

Diane S. Keeney
dkeeney@cumberlandpharma.com
Small Business Information at Submission:

CUMBERLAND PHARMACEUTICALS, INC.
CUMBERLAND PHARMACEUTICALS INC. 2525 WEST END AVE, STE 950 NASHVILLE, TN 37203

EIN/Tax ID: 621765329
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
VANDERBILT UNIVERSITY
VANDERBILT UNIVERSITY
Medical Center
NASHVILLE, TN 37203 6869
RI Type: Nonprofit college or university